Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Relay Therapeutics (RLAY) EBITDA Margin (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed EBITDA Margin for 6 consecutive years, with 780.71% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin changed N/A to 780.71% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1789.24% through Dec 2025, up 159343.0% year-over-year, with the annual reading at 1789.35% for FY2025, 159331.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 780.71% at Relay Therapeutics, up from 10424.82% in the prior quarter.
  • The five-year high for EBITDA Margin was 8030500.0% in Q4 2023, with the low at 83011.76% in Q2 2023.
  • Average EBITDA Margin over 5 years is 484816.28%, with a median of 11257.73% recorded in 2021.
  • The sharpest move saw EBITDA Margin tumbled -93915691bps in 2021, then surged 805600751bps in 2023.
  • Over 5 years, EBITDA Margin stood at 12090.65% in 2021, then tumbled by -111bps to 25507.51% in 2022, then soared by 31583bps to 8030500.0% in 2023, then tumbled by -100bps to 822.91% in 2024, then increased by 5bps to 780.71% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 780.71%, 10424.82%, and 990.18% for Q4 2025, Q2 2025, and Q1 2025 respectively.